In one of the largest studies to date, a team of AIDS researchers concludes that name-based reporting programs for HIV infection are not producing specific public health benefits in the effort to control the AIDS epidemic. The study is the first multi-state, random survey to examine how HIV name-reporting affects public health interventions. It was conducted by a team from UC San Francisco, UC Berkeley, eight state health departments, and the Centers for Disease Control and Prevention.
The research results, published in the November 16 issue of Annals of Internal Medicine, present more data in the ongoing policy debate over the advantages and disadvantages of name-reporting of HIV infection. This reporting system is required by law in 31 states, but it remains controversial. All states require name-reporting of an AIDS diagnosis.
Name-reporting of HIV infection--which also is known as name-based HIV surveillance--requires that all adults who test positive for HIV be reported by name to a public health department unless the HIV test is done at a site that specifically offers anonymous HIV testing. Most states, including the majority with laws requiring HIV name- reporting, provide some sites where an anonymous HIV test can be obtained. In anonymous HIV testing, the result is linked to an identification number and not a person's name.
HIV name-reporting, according to some advocates, is beneficial because it sets up the potential for the health department to assist HIV-positive individuals in receiving timely medical treatment and in notifying their sex and needle-sharing partners about possible exposure to the AIDS virus. Opponents of HIV name-reporting have feared that the policy could be a deterrent to persons seeking care for HIV.
"We found both the positive and the negative ways that name-based surveillance programs supposedly affect public health interventions-specifically partner notification and access to health care-to be exaggerated. Our data showed no effect one way or the other. The findings do open up discussion as to whether public health funds spent on these interventions are being used in the most effective way," said Dennis Osmond, PhD, lead author of the Annals article and associate professor in the UCSF Department of Epidemiology and Biostatistics and UCSF Center for AIDS Prevention Studies (CAPS).
In understanding this subject, Osmond also noted that name-based HIV reporting should not be confused with name-based AIDS reporting. HIV reporting applies to persons who are undergoing testing to find out if they have HIV infection. AIDS reporting applies to HIV-positive persons who are newly diagnosed with the disease AIDS or its complications. This diagnosis, which is made by a health care provider, is always attached to an individual's name and is reported to a public health department in all 50 states.
The study involved close to 2,000 HIV-positive persons who were newly diagnosed with AIDS during 1995-96. At the time, participants came from five states that had name-based reporting policies (Arizona, Colorado, Mississippi, Missouri, North Carolina) and three that did not (Texas, Oregon, and New Mexico). New Mexico has since passed a name-based surveillance law.
Personal interviews took place with all study participants, and they self-reported their experience with HIV testing, getting into care for HIV, contact with the health department, and notification to at-risk sex and needle-sharing partners. The sample included men who had sex with men, persons who used injection drugs, and heterosexual persons randomly selected from newly reported AIDS cases in each state.
The main study findings include:
"I expect that HIV name-reporting will remain controversial because it raises several sets of controversial issues, such as the potential effect of delaying or avoiding an HIV test, the value for monitoring the HIV/AIDS epidemic, and the value of public health interventions. However, separating the issues about surveillance itself from the issues about the use of surveillance to deliver the public health interventions that we evaluated would help focus the debate," Osmond said.
Arthur Reingold, MD, professor of epidemiology in the School of Public Health at UC Berkeley, was principal investigator of the study. Co-investigators were Andrew Bindman, MD; Karen Vranizan, MA; Frederick Hecht, MD, and Dennis Keane, MPH, of UCSF and San Francisco General Hospital Medical Center; and J. Stan Lehman, MPH, of CDC.
The study was funded by CDC as part of the Multistate Evaluation of Surveillance for HIV (MESH) project.
UCSF CAPS is part of the UCSF AIDS Research Institute, a campuswide enterprise without walls that encompasses all UCSF AIDS programs under a single umbrella and includes close to 1,000 investigators. Thomas J. Coates, PhD, is director of UCSF CAPS and executive director of UCSF ARI.
Annals of Internal Medicine